Catalog No.S1569 Synonyms: AGN190168
Molecular Weight(MW): 351.46
Tazarotene is a retinoid prodrug of tazarotenic acid, which is a RAR agonist, used to treat psoriasis, acne, and sun damaged skin.
Purity & Quality Control
Choose Selective Retinoid Receptor Inhibitors
|Description||Tazarotene is a retinoid prodrug of tazarotenic acid, which is a RAR agonist, used to treat psoriasis, acne, and sun damaged skin.|
Tazarotene causes ERK activation, RB tumor suppressor protein hypophosphorylation, G0 arrest, and myeloid differentiation in HL-60 human myeloblastic leukemia cells. Tazarotene could propel either early or late portions of the period leading to differentiation and G0 arrest and is interchangeable with an RARalpha-selective ligand.  Tazarotene therapy regulates gene transcription via interaction with specific nuclear retinoic acid receptors (RARs), thereby modulating the three key pathogenic factors in psoriasis.  Tazarotene inhibits the proliferation of fibroblasts and synthesis of DNA and collagen.  Tazarotene down-regulates markers of keratinocyte differentiation, keratinocyte proliferation, and inflammation. Tazarotene also up-regulates three novel genes TIG-1 (tazarotene-induced gene-1), TIG-2, and TIG-3, which may mediate an antiproliferative effect.  Tazarotene causes growth suppression in retinoid-responsive breast cancer cell lines by up-regulating TIG3. 
|In vivo||Tazarotene treatment reduces the number and size of microscopic basal cell carcinomas (BCCs) in UV-treated Ptch1+/− mice. Tazarotene treatment reduces the number and size of microscopic basal cell carcinomas (BCCs) in ionizing radiation-treated Ptch1+/− mice. |
-  Yen A, et al. Mol Pharmacol, 2004, 66(6), 1727-1737.
-  Duvic M, et al. Expert Opin Investig Drugs, 1997, 6(10), 1537-1551.
-  Ogawa A, et al. Jpn J Pharmacol, 1998, 76(3), 317-319.
|In vitro||DMSO||10 mg/mL (28.45 mM)|
|Ethanol||10 mg/mL (28.45 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02886702||Recruiting||Plaque Psoriasis||Fougera Pharmaceuticals Inc.||August 2016||Phase 3|
|NCT02886715||Recruiting||Acne Vulgaris||Fougera Pharmaceuticals Inc.||August 2016||Phase 3|
|NCT02721173||Completed||Acne Vulgaris||All India Institute of Medical Sciences, Bhubaneswar||April 2016||Phase 4|
|NCT02218034||Completed||Acne Vulgaris||Allergan||August 2014||Phase 1|
|NCT02411955||Completed||Acne Vulgaris||Taro Pharmaceuticals USA||June 2014||Phase 1|
|NCT02267746||Completed||Acne Vulgaris||Actavis Inc.||June 2014||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.